Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
Abstract Background An infection with high-risk human papillomavirus (HPV) is the obligatory aetiological factor for the development of cervical cancer. In Switzerland, the prevention strategy for cervical cancer is based on primary prevention via HPV vaccination and secondary prevention with an opp...
Main Authors: | André B. Kind, Andrew Pavelyev, Smita Kothari, Nadia El Mouaddin, Aurélie Schmidt, Edith Morais, Patrik Guggisberg, Florian Lienert |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | BMC Public Health |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12889-020-08840-0 |
Similar Items
-
Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium
by: Steven Simoens, et al.
Published: (2021-04-01) -
The distribution and pathogenic risk of non‐9‐valent vaccine covered HPV subtypes in cervical lesions
by: Mingjun Ma, et al.
Published: (2022-03-01) -
Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery
by: Ilias Gountas, et al.
Published: (2023-01-01) -
HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study
by: Rosa De Vincenzo, et al.
Published: (2021-06-01) -
Association of provider HPV vaccination training with provider assessment of HPV vaccination status and recommendation of HPV vaccination
by: Ikponmwosa Osaghae, et al.
Published: (2022-11-01)